These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 20406018

  • 1. Recognition and management of antibodies to human platelet antigens in platelet transfusion-refractory patients.
    Vassallo RR.
    Immunohematology; 2009; 25(3):119-24. PubMed ID: 20406018
    [Abstract] [Full Text] [Related]

  • 2. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
    Wang J, Xia W, Deng J, Xu X, Shao Y, Ding H, Chen Y, Liu J, Chen D, Ye X, Santoso S.
    Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
    [Abstract] [Full Text] [Related]

  • 3. Platelet transfusion refractoriness associated with HPA-1a (Pl(A1)) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions.
    Pappalardo PA, Secord AR, Quitevis P, Haimowitz MD, Goldfinger D.
    Transfusion; 2001 Aug; 41(8):984-7. PubMed ID: 11493728
    [Abstract] [Full Text] [Related]

  • 4. Management of the Platelet Refractory Patient.
    Forest SK, Hod EA.
    Hematol Oncol Clin North Am; 2016 Jun; 30(3):665-77. PubMed ID: 27113003
    [Abstract] [Full Text] [Related]

  • 5. Determination in vivo viability of a transfused platelet product by corrected count increment and percentage platelet response.
    Thuku NW, Shikuku K, Mbugua A.
    Pan Afr Med J; 2017 Jun; 27():226. PubMed ID: 28979628
    [Abstract] [Full Text] [Related]

  • 6. HPA antibodies in Algerian multitransfused patients: Prevalence and involvement in platelet refractoriness.
    Brouk H, Bertrand G, Zitouni S, Djenouni A, Martageix C, Griffi F, Kaplan C, Ouelaa H.
    Transfus Apher Sci; 2015 Jun; 52(3):295-9. PubMed ID: 25620758
    [Abstract] [Full Text] [Related]

  • 7. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
    Basire A, Picard C.
    Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The role of alloantibodies against human platelet antigen-15 in multiply platelet transfused patients.
    Matsuhashi M, Tsuno NH, Sone S, Mishima Y, Nagura Y, Watanabe-Okochi N, Ikeda T, Kashiwase K, Fukuda S, Iriyama T, Hyodo H, Yamashita T, Kamei Y, Arai S, Minami M, Fujii T, Kurokawa M, Tozuka M, Takahashi K, Santoso S.
    Transfusion; 2014 Apr; 54(4):1093-9. PubMed ID: 24147542
    [Abstract] [Full Text] [Related]

  • 10. Strategies for managing refractoriness to platelet transfusions.
    Dan ME, Schiffer CA.
    Curr Hematol Rep; 2003 Mar; 2(2):158-64. PubMed ID: 12901147
    [Abstract] [Full Text] [Related]

  • 11. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
    Jia Y, Li W, Liu N, Zhang K, Gong Z, Li D, Wang L, Wang D, Jing Y, Wang J, Shan X.
    Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
    [Abstract] [Full Text] [Related]

  • 12. How do I … manage the platelet transfusion-refractory patient?
    Juskewitch JE, Norgan AP, De Goey SR, Duellman PM, Wakefield LL, Gandhi MJ, Stubbs JR, Kreuter JD.
    Transfusion; 2017 Dec; 57(12):2828-2835. PubMed ID: 28960321
    [Abstract] [Full Text] [Related]

  • 13. Posttransfusion purpura following bone marrow transplantation.
    Evenson DA, Stroncek DF, Pulkrabek S, Perry EH, Radford J, Miller JS, Verfaillie C.
    Transfusion; 1995 Aug; 35(8):688-93. PubMed ID: 7631411
    [Abstract] [Full Text] [Related]

  • 14. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
    Wiita AP, Nambiar A.
    Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Management of patients refractory to platelet transfusion.
    Chockalingam P, Sacher RA.
    J Infus Nurs; 2007 Oct; 30(4):220-5. PubMed ID: 17667077
    [Abstract] [Full Text] [Related]

  • 17. Primary refractoriness to platelet transfusion caused by Nak(a) antibody alone.
    Fujino H, Ohta K, Taniue J, Nagao N, Hino M, Yamane T, Koh KR, Takeoka Y, Hirose A, Aoyama Y, Nakamae H, Terada Y, Takubo T, Tatsumi N.
    Vox Sang; 2001 Jul; 81(1):42-4. PubMed ID: 11520415
    [Abstract] [Full Text] [Related]

  • 18. Use of HLA- and HPA--matched platelets in alloimmunized patients.
    Kekomäki R.
    Vox Sang; 1998 Jul; 74 Suppl 2():359-63. PubMed ID: 9704468
    [Abstract] [Full Text] [Related]

  • 19. Platelet corrected count increments by apheresis platform.
    Tobian AA, King KE, Borge PD, Fuller AK, Uglik K, Ness PM.
    Transfusion; 2016 Oct; 56(10):2584-2586. PubMed ID: 27572682
    [Abstract] [Full Text] [Related]

  • 20. Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management.
    Panch SR, Guo L, Vassallo R.
    Blood Rev; 2023 Nov; 62():101135. PubMed ID: 37805287
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.